Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261165 | 0.88 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15223381 | 0.88 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL33377881 | 0.88 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL33377838 | 0.88 | CASP3 (0.69) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL22960726 | 0.88 | CASP3 (0.69) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15382522 | 0.83 | CASP3 (0.55) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL6520211 | 0.82 | KMT2A (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29400883 | 0.82 | KMT2A (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL119042 | 0.82 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL11965163 | 0.82 | KMT2A (0.51) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | CASP3 1263/4885KMT2A 4326/4885EPHX2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.